Every 10-Q that AbbVie Inc. (ABBV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ABBV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABBV filings page.
AbbVie delivered strong 2026 mid‑year results, with net revenues of $16,990 million for the quarter and $31,992 million for the first half, up 10% and 11% year over year. Operating earnings reached $6,432 million in Q2 and $10,422 million year‑to‑date, while diluted EPS rose to $2.03 for the quarter and $2.42 for six months.
Growth was led by immunology: Q2 Skyrizi revenues were $5,505 million and Rinvoq $2,525 million, offsetting steep Humira declines. Neuroscience brands including Vraylar, Botox Therapeutic, Ubrelvy, Qulipta and Vyalev posted broad double‑digit growth, while Imbruvica, Mavyret and parts of the aesthetics portfolio contracted.
Cash flows from operations were $7,265 million, supporting $6,148 million in dividends and $1,498 million of share repurchases, alongside issuance of $8,000 million of new senior notes. AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion and recorded a $650 million upfront payment to RemeGen, reinforcing a pipeline that secured multiple FDA and European approvals across Skyrizi, Rinvoq, Venclexta, Epkinly and aesthetics products.
AbbVie reported first‑quarter 2026 results with solid revenue growth but lower earnings. Net revenues rose to $15.0 billion, up 12% year over year, driven by strong expansion of immunology drugs Skyrizi and Rinvoq, neuroscience brands like Vraylar, Botox Therapeutic, Ubrelvy and Qulipta, and aesthetics products including Botox Cosmetic.
Operating earnings increased to $4.0 billion, but net earnings attributable to AbbVie fell to $695 million and diluted EPS to $0.39, mainly due to a $2.4 billion non‑cash increase in contingent consideration liabilities and $744 million of acquired R&D and milestone expense, including a $650 million upfront payment to RemeGen.
AbbVie generated strong operating cash flow of $3.8 billion, raised $8.0 billion through new senior notes, paid $3.1 billion in dividends and repurchased $1.1 billion of stock. The company highlighted a large late‑stage pipeline, new regulatory filings for Skyrizi and Rinvoq, and a voluntary U.S. pricing agreement alongside major planned U.S. manufacturing investments.
AbbVie Inc. reported Q3 2025 results. Net revenues were $15,776 million, up from $14,460 million a year ago, while operating earnings fell to $1,904 million from $3,831 million as the company recorded significant charges. Net earnings were $186 million and diluted EPS was $0.10.
Results reflect acquired IPR&D and milestones expense of $2,680 million in the quarter and intangible asset impairments of $847 million in cost of products sold tied to Resonic and Durysta. Interest expense, net, was $667 million. For the nine months ended September 30, 2025, net revenues were $44,542 million and net earnings were $2,410 million; operating cash flow was $13,812 million.
AbbVie completed or announced portfolio moves: Capstan Therapeutics (cash consideration of $2.1 billion; $1.9 billion recognized in IPR&D), Ichnos Glenmark ISB-2001 license (upfront $700 million), ADARx options (upfront $335 million), Gubra license (upfront $350 million), Nimble Therapeutics acquisition (aggregate $288 million). Subsequent to quarter end, AbbVie acquired Gilgamesh Pharmaceuticals for approximately $900 million upfront. Total equity was a deficit of $2,599 million as of September 30, 2025.